Amneal Pharmaceuticals, Inc.
AMRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.00 | 0.29 | 0.00 | -0.76 |
| FCF Yield | 8.99% | 26.02% | -8.49% | 27.21% |
| EV / EBITDA | 11.21 | 7.43 | 7.09 | 8.33 |
| Quality | ||||
| ROIC | 9.19% | 7.16% | -3.01% | 2.97% |
| Gross Margin | 36.52% | 36.09% | 35.78% | 36.73% |
| Cash Conversion Ratio | -3.99 | -7.09 | -0.26 | 22.76 |
| Growth | ||||
| Revenue 3-Year CAGR | 8.09% | 4.56% | 3.55% | 12,792,809.89% |
| Free Cash Flow Growth | -20.36% | 1,184.09% | -113.14% | -38.80% |
| Safety | ||||
| Net Debt / EBITDA | 5.65 | 5.31 | 6.40 | 6.55 |
| Interest Coverage | 0.96 | 0.97 | -0.60 | 1.12 |
| Efficiency | ||||
| Inventory Turnover | 2.90 | 2.63 | 2.68 | 2.71 |
| Cash Conversion Cycle | 173.91 | 202.92 | 215.87 | 219.84 |